IRE-1-ALPHA INHIBITORS

Compounds which directly inhibit IRE-1 alpha activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Warren Standfield WADE, Zoltan ZUBOVICS, Zhipeng WU, John Bruce PATTERSON, Andras TORO, Yun YANG, Qingping ZENG
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compounds which directly inhibit IRE-1 alpha activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies. Se describen compuestos que inhiben directamente la actividad de IRE-1a in vitro, profármacos y sales farmacéuticamente aceptable de estos. Los compuestos y profármacos son útiles para tratar enfermedades asociadas con la respuesta a proteínas desplegadas o con la degradación dependiente de IRE-1 regulada (RIDD) y pueden utilizarse como agentes únicos o en terapias de combinación.